Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis R. Altman, M. Hochberg, A. Kivitz, A. Gibofsky, D. Solorio, C. Young Osteoarthritis and Cartilage Volume 24, Pages S419-S420 (April 2016) DOI: 10.1016/j.joca.2016.01.756 Copyright © 2016 Terms and Conditions
Figure 1. Continuous responder analysis of the WOMAC pain subscale scores at week 12 in patients with osteoarthritis. Osteoarthritis and Cartilage 2016 24, S419-S420DOI: (10.1016/j.joca.2016.01.756) Copyright © 2016 Terms and Conditions